KYNB · KYNTRA BIO, INC.

NasdaqHealthcareBiotechnology

Kyntra Bio Inc Is A Biopharmaceutical Company Focused On The Development Of Novel Therapies In Oncology And Rare Disease. The Company'S Research Programs Target Cancer And Rare Disease Indications, Including Anemia Associated With Lower-Risk Myelodysplastic Syndrome (Lr-Mds) And Metastatic Castration-Resistant Prostate Cancer (Mcrpc). Itd Pipeline Drug Candidates Include Roxadustat And Fg-3246.

HealthcareNasdaqUSVery Low Float

$26.00

+79.3% latest move

Price & move as of the most recent catalyst (Feb 19) — not a live quote.

FLOAT

3.9M

FREE FLOAT %

96%

SHARES O/S

4.0M

MARKET CAP

$24.8M

EXCHANGE

Nasdaq

COUNTRY

KYNB Catalyst History

Corporate DealsFeb 19, 2025 · 6:16pm ET

KYNBKYNTRA BIO, INC.

FibroGen Sells China Subsidiary to AstraZeneca for Approximately $160 Million

Transaction includes $85 million enterprise value and $75 million net cash held in China.

Be early on the next KYNB spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →